Review of therapy of psoriasis: The prebiologic armamentarium

Dermatologic Clinics

Volumn 22, Issue 4, 2004, Pages 379-388

  Aaronson, David S ^a   Lebwohl, Mark ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM LACTATE; ATORVASTATIN; CALCITRIOL; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN; DIFLORASONE DIACETATE; DITHRANOL; ESTARGEL; FLUOCINONIDE; FLUTICASONE PROPIONATE; FOLIC ACID; GEMFIBROZIL; HYDROCHLOROTHIAZIDE; HYDROXYUREA; METHOTREXATE; METHOXSALEN; MOMETASONE FUROATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PSORALEN; RETINOID; SALAZOSULFAPYRIDINE; SALICYLIC ACID; STATIN; TACROLIMUS; TAR; TIOGUANINE; TRIETHANOLAMINE; ULOBETASOL PROPIONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D DERIVATIVE;

ANOREXIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN PSEUDOTUMOR; BURN; CHEILITIS; CLINICAL TRIAL; COUGHING; CUSHING SYNDROME; DERMATITIS; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOMAGNESEMIA; IMMUNE DEFICIENCY; INFECTION; INFECTION SENSITIVITY; IRRITANT DERMATITIS; KIDNEY FAILURE; LIGAMENT CALCINOSIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG FIBROSIS; LYMPHOPROLIFERATIVE DISEASE; MACROCYTIC ANEMIA; MALE GENITAL TRACT CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MYALGIA; NAUSEA; NEPHROTOXICITY; OSTEOPOROSIS; PHOTOSENSITIVITY; PHOTOTHERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PURPURA; PYOGENIC GRANULOMA; REVIEW; SEIZURE; SIDE EFFECT; SKELETON MALFORMATION; SKIN ATROPHY; SKIN CANCER; SKIN DEFECT; SKIN DISEASE; SKIN IRRITATION; SPONTANEOUS ABORTION; SQUAMOUS CELL CARCINOMA; STOMATITIS; T CELL LYMPHOMA; TACHYPHYLAXIS; TELANGIECTASIA; TERATOGENICITY; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; COMBINED MODALITY THERAPY; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PROGNOSIS; PSORIASIS; PUVA THERAPY; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 4344605716     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2004.03.012     Document Type: Review

References (96)

1. Cornell R.C., Stoughton R.B. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol. 121:1985;63-67
2. Du Vivier A., Stoughton R.B. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol. 111(5):1975;581-583
3. Miller J.J., Roling D., Margolis D., Guzzo C. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol. 41(4):1999;546-549
4. Katz H.I., Prawer S.E., Medansky R.S., Krueger G.G., Mooney J.J., Jones M.L., et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica. 183(4):1991;269-274
5. Hutchinson P.E., Marks R., White J. The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. Dermatology. 201(2):2000;139-145
6. Ramsay B., Lawrence C.M., Bruce J.M., Shuster S. The effects of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol. 23(1):1990;73-76
7. Kragballe K., Wildfang I.L. Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res. 282(3):1990;164-167
8. Koo J. Diluting dovonex. Psoriasis Forum. 1:1995;6
9. Lebwohl M. Topical application of calcipotriene and corticosteroids: combination regimens. J Am Acad Dermatol. 37(3 Pt 2):1997;S55-S58
10. Georgiou S., Tsambaos D. Hypercalcemia and hypercalciuria after topical treatment of psoriasis with excessive amounts of calcipotriol. Acta Derm Venereol. 1:1999;79-86
11. Kragballe K., Fogh K., Sogaard H. Long-term efficacy and tolerability of topical calcipotriol in psoriasis: results of an open study. Acta Derm Venereol. 71:1991;475-478
12. Ramsay C.A., Berth-Jones J., Brundin G., Cunliffe W.J., Dubertret L., van de Kerkhof P.C., et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology. 189:1994;260-264
13. Bruce S., Epinette W.W., Funicella T., Ison A., Jones E.L., Loss R. Jr., et al. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol. 31:1994;755-759
14. Lebwohl M., Yoles A., Lombardi K., Lou W. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol. 39:1998;447-450
15. Kaufmann R., Bibby A.J., Stymne B., Cambazard F., Chu A.C., Decroix J., et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 205(4):2002;389-393
16. Patel B., Siskin S., Krazmien B.A., Lebwohl M. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol. 38:1998;1010-1011
17. Ramsay C.A., Schwartz B.E., Lowson D., Papp K., Bolduc A., Gilbert M. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatic combination treatment. Dermatology. 200(1):2000;17-24
18. Brands S., Brakman M., Bos J.D., de Rie M.A. No additional effect of calcipotriol ointment on low-dose narrow-band UVB phototherapy in psoriasis. J Am Acad Dermatol. 41(6):1999;991-995
19. De Rie M.A., Di Nuzzo S., Brands S., Hansen A.B., Bos J.D. Calcipotriol ointment and cream or their vehicles applied immediately before irradiation inhibit UVB-induced erythema. Br J Dermatol. 142(6):2000;1160-1165
20. Speight E.L., Farr P.M. Calcipotriol improves the response of psoriasis to PUVA. Br J Dermatol. 130:1994;79-82
21. Lebwohl M., Hecker D., Martinez J., Sapadin A., Patel B. Interactions between calcipotriene and ultraviolet light. J Am Acad Dermatol. 37:1997;93-95
22. Chandraratna R.A. Tazarotene - first of a new generation of receptor-selective retinoids. Br J Dermatol. 135(Suppl 49):1996;18-25
23. Esgleyes-Ribot T., Chandraratna R.A., Lew-Kaya D.A., Sefton J., Duvic M. Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol. 30(4):1994;581-590
24. Weinstein G.D., Krueger G.G., Lowe N.J., Duvic M., Friedman D.J., Jegasothy B.V., et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol. 37:1997;85-92
25. Lebwohl M., Breneman D.L., Goffe B.S., Grossman J.R., Ling M.R., Milbauer J., et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 39:1998;590-596
26. Kaidbey K., Kopper S.C., Sefton J., Gibson J.R. A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. Int J Dermatol. 40(7):2001;468-471
27. Koo J., Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. versus mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol. 40:2001;210-212
28. Lebwohl M. Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol. 43:2000;S43-S46
29. Koo J.Y. Tazarotene in combination with phototherapy. J Am Acad Dermatol. 39:1998;S144-S148
30. Hecker D., Worsley J., Yueh G., Kuroda K., Lebwohl M. Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol. 41:1999;927-930
31. Goeckerman W.H. Treatment of psoriasis. Northwest Med. 24:1925;229-231
32. Ingram J.T. The approach to psoriasis. BMJ. 2:1953;591-594
33. Levine M.J., White H.A., Parrish J.A. Components of the Goeckerman regimen. J Invest Dermatol. 73:1979;170-173
34. Fitzpatrick T.B. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 124:1988;869-871
35. Berne B., Blom I., Spangberg S. Enhanced response of psoriasis to UVB therapy after pretreatment with a lubricating base: a single-blind controlled study. Acta Derm Venereol. 70:1990;474-477
36. Lebwohl M., Martinez J., Weber P., DeLuce R. Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. J Am Acad Dermatol. 32:1995;469-471
37. Stern R.S., Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up study. Cancer. 73:1994;2759-2764
38. Hecker D., Lebwohl M., Siskin S. Topical calcipotriene in combination with UVB phototherapy for psoriasis. Int J Dermatol. 36:1997;302-303
39. Molin L. Topical calcipotriol combined with phototherapy for psoriasis: the results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group. Dermatology. 198:1999;375-381
40. Lebwohl M., Drake L., Menter A., Koo J., Gottlieb A.B., Zanolli M., et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol. 45:2001;544-553
41. Paul B.S., Momtaz K., Stern R.S., Arndt K.A., Parrish J.A. Combined methotrexate-UVB therapy in the treatment of psoriasis. J Am Acad Dermatol. 7:1982;758-762
42. Stern R.S., Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol. 91:1988;120-124
43. Stern R.S. Genital tumors among men with psoriasis exposed to radiation. The Photochemotherapy Follow-up Study. N Engl J Med. 322:1990;1093-1097
44. Stern R.S., Nichols K.T., Vakeva L.H. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and UVA radiation. The PUVA follow-up study. N Engl J Med. 336:1997;1041-1045
45. Lynch W.S., Roenigk H.H. Jr. Essentials for PUVA therapy: guidelines for photochemotherapy. Cutis. 20:1977;494-501
46. British Photodermatology Group British Photodermatology Group guidelines for PUVA. Br J Dermatol. 130:1994;246-255
47. Schmoll M., Henseler T., Christophers E. Evaluation of PUVA, topical corticosteroids and the combination of both in the treatment of psoriasis. Br J Dermatol. 99:1978;693-702
48. Morison W.L., Parrish J.A., Fitzpatrick T.B. Controlled study of PUVA and adjunctive topical therapy in the management of psoriasis. Br J Dermatol. 98:1978;125-132
49. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol. 41(Suppl):1999;S22-S24
50. Tanew A., Guggenbichler A., Honigsmann H., Geiger J.M., Fritsch P. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol. 25:1991;682-684
51. Bollag W., Holdener E.E. Retinoids in cancer prevention and therapy. Ann Oncol. 3:1992;513-526
52. Van de Kerkhof P.C., de Rooij M.J. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporine treatment: response to long-term acitretin maintenance. Br J Dermatol. 136:1997;275-278
53. Bavinck J.N., Tieben L.M., Van der Woude F.J., Tegzess A.M., Hermans J., ter Schegget J., et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol. 13:1995;1933-1938
54. Morison W.L., Momtaz K., Parrish J.A., Fitzpatrick T. Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol. 6:1982;46-51
55. Coven T.R., Burack L.H., Gilleaudeau R., Keogh M., Ozawa M., Krueger J.G. Narrowband UVB produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UVB. Arch Dermatol. 133:1997;1514-1522
56. Tanew A., Radakovic-Fijan S., Schemper M., Honigsmann H. Narrowband UVB phototherapy versus photochemotherapy in the treatment of chronic plaque-type psoriasis: a paired comparison study. Arch Dermatol. 135:1999;519-524
57. Dawe R.S., Cameron H., Yule S., Man I., Wainwright N.J., Ibbotson S.H., et al. A randomized controlled trial of narrowband UVB versus bath-psoralen plus UVA photochemotherapy for psoriasis. Br J Dermatol. 148:2003;1194-1204
58. Roenigk H.H. Jr., Auerbach R., Maibach H., Weinstein G., Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 38:1998;478-485
59. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol. 288:1993;466-469
60. Lawrenz-Wolf B., Wehinger H. Reactivation of sunburn by methotrexate. Klin Paediatr. 200:1988;335-338
61. Kremer J.M., Alarcon G.S., Weinblatt M.E., Kaymakcian M.V., Macaluso M., Cannon G.W., et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury I patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum. 40:1997;1829-1837
62. Kono H., Inokuma S., Matsuzaki Y., Nakayama H., Yamazaki J., Hishima T., et al. Two cases of methotrexate induced lymphomas in rheumatoid arthritis: an association with increased serum IgE. J Rheumatol. 26:1999;2249-2253
63. Solganick J., Tan M.H., Lebwohl M. Systemic treatments: adverse effects of methotrexate. Psoriasis Forum. 3:1997;5
64. Whiting-O'Keefe Q.E., Fye K.H., Sack K.D. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 90:1991;711-716
65. Bawle E.V., Conard J.V., Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology. 57:1998;51-55
66. Moy R.L., Kinston T.P., Lowe N.J. Isotretinoin versus etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol. 121:1985;1297-1301
67. Honigsmann H., Wolff K. Isotretinoin-PUVA for psoriasis. Lancet. 1:1983;236
68. Roenigk R.K., Gibstine C., Roenigk H.H. Jr. Oral isotretinoin followed by psoralens and ultraviolet A or ultraviolet B for psoriasis. J Am Acad Dermatol. 13:1985;153-155
69. Larsen F.G., Jakobsen P., Knudsen J., Weismann K., Kragballe K., Nielsen-Kudsk F. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol. 100:1993;623-627
70. Vahlquist C., Olsson A.G., Lindholm A., Vahlquist A. Effects of gemfibrozil on hyperlipidemia in acitretin-treated patients: results of a double-blind cross-over study. Acta Derm Venereol. 75:1995;377-380
71. DiGiovanna J.J., Sollitto R.B., Abangan D.L., Steinberg S.M., Reynolds J.C. Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol. 131:1995;1263-1267
72. Wilson D.J., Kay V., Charig M., Hughes D.G., Creasy T.S. Skeletal hyperostosis and extraosseous calcification in patients receiving long-term etretinate. Br J Dermatol. 119:1988;597-607
73. Lowe N.J., Prystowsky J.H., Bourget T., Edelstein J., Nychay S., Armstrong R. Acitretin plus UVB therapy for psoriasis: comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol. 24:1991;591-594
74. McKenna D.B., Murphy G.M. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years experience using low-dose acitretin. Br J Dermatol. 140:1999;656-660
75. van de Kerkhof P.C., Cambazard F., Hutchinson P.E., Haneke E., Wong E., Souteyrand P., et al. The effect of addition of calcipotriol ointment (50microg/g) to acitretin therapy in psoriasis. Br J Dermatol. 138:1998;84-89
76. Ellis C.N., Gorsulowsky D.C., Hamilton T.A., Billings J.K., Brown M.D., Headington J.T., et al. Cyclosporine improves psoriasis in a double-blind study. JAMA. 256:1986;3110-3116
77. Ellis C.N., Fradin M.S., Messana J.M., et al. N Engl J Med. 324:1991;277-284
78. Jensen P., Hansen S., Moller B., Leivestad T., Pfeffer P., Geiran O., et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 40:1999;177-186
79. Srivastava T., Zwick D.L., Rothberg P.G., Warady B.A. Posttransplandt lymphoproliferative disorder in pediatric renal transplantation. Pediatr Nephrol. 13:1999;748-754
80. van der Borne B.E., Landewe R.B., Houkes I., Schild F., van der Heyden P.C., Hazes J.M., et al. No increased risk of malignancies and mortality in cyclosporine A-treated patients with rheumatoid arthritis. Arthritis Rheum. 41:1998;1930-1937
81. Corazza M., Zampino M.R., Montanari A., Altieri E., Virgili A. Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine. Dermatology. 206:2003;330-333
82. Zachariae H., Kragballe K., Hansen H.E., Marcussen N., Olsen S. Renal biopsy findings in long-term cyclosporine treatment of psoriasis. Br J Dermatol. 136:1997;531-535
83. Lowe N.J., Wieder J.M., Rosenbach A., Johnson K., Kunkel R., Bainbridge C., et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol. 35:1996;710-719
84. Raman G.V., Campbell S.K., Farrer A., Albano J.D., Cook J. Modifying effects of amlodipine on cyclosporine A-induced changes in renal function in patients with psoriasis. J Hypertens Suppl. 16:1998;S39-S41
85. Raddadi A.A., Baker Damanhoury Z. Cyclosporin and pregnancy. Br J Dermatol. 140:1999;1197-1198
86. Ohtsuki M., Nakagawa H., Sugai J., Ozawa A., Ohkido M., Nakayama J., et al. Long-term continuous versus intermittent cyclosporine: therapy for psoriasis. J Dermatol. 30:2003;290-298
87. Ho V.C., Griffiths C.E., Berth-Jones J., Papp K.A., Vanaclocha F., Dauden E., et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol. 44:2001;643-651
88. Woo J., Propper D.J., Thomson A.W. Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. Immunology. 71:1990;551-555
89. Woo J., Stephen M., Thomsom A.W. Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506. Immunology. 65:1988;153-155
90. Jones E.L., Epinette W.W., Hackney V.C., Menendez L., Frost P. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol. 65:1975;537-542
91. Marinari R., Fleischmajer R., Schragger A.H., Rosenthal A.L. Mycophenolic acid in the treatment of psoriasis: long-term administration. Arch Dermatol. 113:1977;930-932
92. Mathew T.H. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantaion: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 65:1998;1450-1454
93. Layton A.M., Sheehan-Dare R.A., Goodfield M.J., Cotterill J.A. Hydroxyurea in the management of therapy resistant psoriasis. Br J Dermatol. 121:1989;647-653
94. Smith C.H. Use of hydroxyurea in psoriasis. Clin Exp Dermatol. 24:1999;2-6
95. Silvis N.G., Levine N. Pulse dosing of thioguanine in recalcitrant psoriasis. Arch Dermatol. 135:1999;433-437
96. Salvarani C., Macchioni P., Olivieri I., Marchesoni A., Cutolo M., Ferraccioli G., et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol. 28:2001;2274-2282